Introduction
Ablation is used increasingly for rhythm control in patients with symptomatic atrial fibrillation (AF) and seems to be more effective than medical rhythm control. 1 However, recurrence of AF after ablation is not uncommon, and several factors such as advanced age, concomitant cardiovascular disease, and long AF duration are all predictors that have been associated with a higher recurrence rate after ablation. [2] [3] [4] Since the introduction of ablation for AF in 1998, both the operator experience and the ablation techniques (improved 3D mapping systems, force sensing, and high irrigation flow catheters, single-shot devices for pulmonary vein isolation such as the cryoballoon) have evolved considerably, which could potentially improve outcome. Furthermore, there has been a change in patient selection broadening the indication for AF ablation to include older patients with more co-morbidity and less prior use of antiarrhythmic drugs.
The net effect of these changes on the outcome of ablation for AF over the past decade was the subject of the present investigation. 5 Through nationwide Danish registers the aim of this study was to investigate trends in 1 year AF recurrence after ablation from 2005 to 2014, and to identify risk factors associated with recurrent AF.
Methods
Data sources: In this register based cohort study information on demographics, comorbidities, procedures, concomitant medication, and outcome variables were identified using three different nationwide Danish registers. The Civil Registration System holds data on age, sex, and vital status of patients where all deaths are registered within 14 days of occurrence. The Danish National Patient Register holds information on every hospital admission in Denmark since 1978, in which each hospitalization is registered at discharge with one primary diagnosis and, if applicable, one or more secondary diagnoses according to the International Classification of Diseases; the 10th revision (ICD-10) since 1994. The Danish National Patient Register also holds information on operations and procedures including ablation and cardioversions performed in Denmark. These procedures have been registered since 1996 and coded according to the Nordic Classification of Surgical Procedures (NCSP) by The Nordic Medico-Statistical Committee. Comprising data on date, quantity, strength, formulation, and affiliation of the prescribing physician, all prescriptions dispensed from Danish pharmacies have been accurately registered in The Danish Registry of Medicinal Product Statistics since 1995, and coded according to the Anatomical Therapeutic Chemical (ATC) classification system. Study cohort: All Danish patients undergoing a first-time ablation for AF between 2005 and 2014 were included in the study. Ablation procedures for AF were identified using procedure codes for AF ablation (NCSP: BFFB04).
Study groups: Patients were allocated by date of ablation procedure date five groups by calendar year (2005-2006, 2007-2008, 2009-2010, 2011-2012, and 2013-2014) . Follow-up time was 1 year from date of ablation; hence the follow-up period was from 2005 to 2015.
Outcome variables: Recurrent AF was defined as a composite of hospital admission (one or more days) with AF as primary diagnosis (ICD-10 I48), cardioversion for AF (NCSP: BFFA00, BFFA01, BFFA04), second ablation for AF (NCSP: BFFB04), or redeemed prescription of an antiarrhythmic drugs (amiodarone C01BD01, dronedarone C01BD07, class 1C anti-arrhythmic medication, C01BC) 90 days or more after ablation.
Demographic information on age, sex, and vital status was identified using The Civil Registration System. Comorbidities as chronic kidney disease, heart failure, ischaemic stroke, haemorrhagic stroke, ischaemic heart disease, vascular disease, liver disease, cancer, and clinical features as duration of AF prior to ablation, cardioversion 1 year prior to ablation, prior percutaneous coronary interventions, prior coronary artery bypass grafting, were identified using The Danish National Patient Register. Hyperthyroidism, hypothyroidism, diabetes mellitus, hypertension, and concomitant medication (RAS-inhibitors, loop diuretics, non-loop diuretics, beta blockers, anti-adrenergic drugs, amiodarone, calcium channel blockers, acetylic salicylic acid, non-steroid anti-inflammatory drugs, adenosine diphosphate receptor inhibitor, digoxin, class 1C antiarrhythmic medication) were identified using The Danish Registry of Medicinal Product Statistics (see Supplementary material online, Appendix Table S1 ). The Danish nationwide registries include data on all residents regardless of participation in the labour market, and therefore are not affected by selection bias caused by including selected age groups, hospitals, or health insurance systems.
Statistics
Categorical data were presented as counts with percentages. Odds ratio (OR) with 95% confidence intervals (95% CI) was calculated using logistic regression analyses as multivariable adjusted for age, sex, duration of AF, hypertension, heart failure, diabetes mellitus, vascular disease, chronic kidney disease, and cardioversion 1 year prior to ablation.
Long-term follow-up for all 2-year time-groups was presented as Aalen-Johansson cumulative incidences curves accounting for competing risk of death. Ten-year follow-up was available for the 2005-2006 group and two and a half year in the 2013-2014 group. A long-term follow-up analysis was also performed for the CHA 2 DS2-VASc groups 0, 1, and >1 over 10 years.
A sensitivity analysis was conducted using propensity score matching 1:1 on AF duration, cardioversion prior to ablation, amiodarone, beta blocker, class 1C anti-arrhythmic medication, loop diuretics, RAS inhibitors, verapamil, chronic kidney disease, chronic obstructive pulmonary disease, diabetes, heart failure, hypertension, ischaemic heart disease, liver disease, and vascular disease with exact match on sex and age.
Data management and statistical analyses were conducted using R statistics 
Results

Time trends in patient characteristics
A total of 5425 patients were identified with first-time ablation between 2005 and 2014 whereof 5392 (99%) patients were eligible to enter the study ( Figure 1 Table 1) .
Time trends in 1 year AF recurrence
With up to 1 year of follow-up, we observed a consistent decrease in the incidence of recurrent AF. The incidence decreased substantially from 45% in 2005-2006 to 31% in 2013-2014 with an adjusted odds ratio (95% CI) of 0.57 (0.47-0.68, P < 0.001) ( Figure 2 ). In the subgroup analyses, the decreased risk of recurrent AF over time was
Temporal trends in atrial fibrillation recurrence rates consistent across most patient groups (Supplementary material online, Figure S1 ). Though, the risk of recurrent AF remained statistically unchanged in patients undergoing cardioversion prior to ablation, and in patients with heart failure, diabetes, and chronic renal disease.
Risk factors for 1 year atrial fibrillation recurrence
Men had a significantly decreased risk of recurrent AF, while hypertension and cardioversion prior to ablation and AF duration more than 2 years all significantly increased risk of recurrent AF (Figure 3) . Especially Cardioversion within 1 year prior to ablation increased risk of 1 year recurrence with an OR (95%) of 1.40 (1.17-1.67) (Figure 3 ).
Long-term atrial fibrillation recurrence
Patients were included in the study by the year of ablation, hence the length of the follow-up periods varied. The shortest follow-up period was in the 2013-2014 group (maximum of 2 years) while the 2005-2006 group had the longest follow-up period (maximum of 11 years) ( Figure 4) . Most recurrences of AF occurred within the first 2 years illustrated by the steeper slope followed by more horizontal plateau indicating decreased recurrence rates after 2 years.
Patients stratified by CHA 2 DS 2 -VASc score 0, 1, and >1 had different risks of recurrent AF after 10 years. The lowest risk was found in patients with a score of 0 with a recurrence rate after 10 years of 70.3% compared 74.2% with patients with a score of 1 (P < 0.001) ( Figure 5) . Although the recurrence rate after 10 years was 78.3% in patients with a score >1 this was non-significant from patients with a score of 1 (P = 0.820).
Individual endpoints
The main driver of the composite endpoint of recurrent AF was admission with AF (44.3% to 50.6%), followed cardioversion for AF (18.2% to 28.7%) and second ablation (14.2% to 24.1%). Antiarrhythmic drugs of amiodarone (5.8% to 11.5%) and flecainide (1.4% and 3.6%) were the individual endpoints with lowest impact on the composite endpoint (see Supplementary material online, Appendix Table S2 Table S3 ).
Sensitivity analysis
In the sensitivity analysis, the propensity score match was 96% between the two time period groups with 467 patients in each group The results from this analysis were similar to the results from the analysis including the two antiarrhythmic drugs in the composite endpoint (see Supplementary material online, Appendix Table S4 ).
Discussion
In this nationwide study, we examined the risk of recurrent AF after radiofrequency ablation in an unselected nationwide sample of patients with AF over a 10-year period. The major findings of the study were: (i) One year recurrence rates decreased substantially from 45% to 31% and the risk almost halved; (ii) Risk factors for recurrence were female gender, hypertension, longer AF duration and cardioversion prior to ablation; (iii) Long-term follow-up also showed a consistent time dependent evolvement towards lower recurrence rates and a better outcome. The decreased risk of recurrent AF could be due to improved patient selection, better ablation techniques, and increased experience with the procedure.
In 2005, the first worldwide, multicentre survey on catheter ablation was published using data from 181 centres from 1995-2002. It indicated a 52% chance of AF free survival with a corresponding 48% risk of recurrent AF over a mean of 12 months follow-up. 6 The second worldwide multicentre survey on catheter ablations performed from 2003-2006, showed that the success rate had increased to 70% with a 30% risk of recurrent AF, over a mean follow-up period of 18 months. 7 These findings are very similar to the data reported in our study with a 45% risk of recurrent AF found in the earliest period (2002 to 2003) and 31% the latest (2013-2014). The 1-year freedom of AF rates after a single ablation procedure was investigated in a meta-analysis including studies conducted between 2008 and 2011. In this meta-analysis a 64% AF free survival, equal to a recurrence rate of 36%, was found. 8 This again was in concordance with the recurrence rates found in our study. The ablation cohort in our study was a mixed cohort of both paroxysmal and non-paroxysmal AF patients. It is known that recurrence rates of AF are lower in patients with paroxysmal AF compared with patients with non-paroxysmal AF with an up to 50% increased risk of AF recurrence when comparing non-paroxysmal AF with paroxysmal 
AF. 9 A differentiation between patients with paroxysmal and nonparoxysmal AF would therefore be desirable but was not feasible in the current study design. Cardioversion of AF is only indicated in patients with persistent AF, since paroxysmal AF by nature is selflimiting, and permanent AF is defined as a chronic state of AF. An attempt towards differentiating between patients with persistent and paroxysmal AF was therefore performed by identifying patients who underwent cardioversion prior to the ablation procedure. The recurrence rate of AF 1 year after ablation was as high as 60% in the 2013-2014 group compared with only 30% in the same period in patients without a cardioversion prior to ablation. When combining all the year groups this gave an OR (95%) of 1.40 (1.17-1.67) which was very similar to the result found by Bhargava et al. 9 (2009) with a hazard ratio (95% CI) of 1.53 (1.15-2.03) for AF free survival with paroxysmal AF compared with non-paroxysmal AF. Female sex increased risk of recurrent AF of approximately 20% compared with male sex. The role of gender and risk of recurrent AF after ablation is a controversial finding as female sex is both a known independent risk factor 9-11 but also protective of recurrent AF 3, 12 with hazard ratios of recurrent AF in female compared with male ranging from 0.09 to 2. 19 . The impact of sex may relate to differences in the anatomy of the heart or possibly the existence of more nonpulmonary vein triggers found in females. 13 Atrial fibrillation duration prior to ablation procedure for more than 2 years increased risk of recurrent AF by 14%. The risk of recurrent AF after ablation in patients with longstanding AF has previously been reported as approximately twice as high as in patients with paroxysmal or short duration of persistent AF. 3, 11, 14 The reason for the more subtle risk incretion in our study compared with other studies could be explained by the method of identifying AF duration in our design which differs from previous studies. Onset AF was defined by first diagnosis of AF whereas prior studies rely on patient information from clinical visits and medical records. Previously long-term follow-up after ablation procedure has been limited to a maximum of 5 years and in smaller cohorts. 8 In our study, we present 2326 patients with a follow-up of 6 years and from these patients 676 had an extensive 10 years follow-up. Pooled data from Ganesan et al. (2013) showed that 46.9% of patients had recurrent AF 5 years after a single ablation procedure with considerable heterogeneity (I 2 = 87.6%) within the studies included. With the highest recurrence rate being 78.6% and the lowest 18.9% (paroxysmal AF). In our study the 5 year follow-up recurrence rate of AF was between 60% (2011-2012) and 73% (2002) (2003) . Since our cohort consisted of patients with both paroxysmal and persistent AF the recurrence rates are similar to the success rates of prior studies. Although the risk of recurrent AF after first-time ablation has decreased over time, the risk is still high with 37% within the first year in 2013-2014. In this study, recurrent AF was defined as a composite of hospital admission with AF, cardioversion of AF, second ablation procedure, or redeemed prescription for an anti-arrhythmic drug. In the existing literature, there is a great variation in the reported number of patients with AF free survival after 1 year but in a recent metaanalysis the pooled overall 1-year AF freedom was 64% (95% CI 58%-70%), this is equal to a recurrence rate of 36% (95% CI 30-42%). 15 In our study, highest recurrence rate was 45% in [2005] [2006] and lowest was 31% in 2013-2014. This is very similar to the results from the meta-analysis. In our study, both hypertension and cardioversion prior to ablation were associated with an increased risk of recurrent AF. Advanced age, longer AF duration, hypertension, and heart failure are all predictors that have been significantly associated with a poorer outcome after a single ablation procedure. [2] [3] [4] 16 Nevertheless, in a systematic review from 2010 the only risk factor for recurrent AF identified was non-paroxysmal AF with a 60% increased chance of recurrence. 17 The first ablations used lesion patterns known from the openchest Cox maze procedure but this was later changed when Haïssaguerre and colleagues invented segmental pulmonary vein isolation, which still remains a cornerstone in modern day ablation. 18 Over the time course of our study period, enhanced ablation techniques like cryo-ablation, circular radio frequency ablation catheters, 3D mapping systems, have emerged. These new features could all potentially improve the outcome of the ablation and thereby decrease the risk of recurrent AF. 19 In our study design no data on catheter types or techniques were available disabling investigation of recurrence rates with these individual techniques.
We found a significant change in age, comorbidities, and concomitant medication in our cohort over time, with older patients with shorter AF duration, less cardioversion, and more hypertension. Same change in patient characteristics has also been found in previous studies. 5, 20 A change in both known and unknown confounders could to some extend explain the decreased risk of recurrent AF found in our study.
Figure 5
Cumulative risk of recurrent atrial fibrillation by congestive heart failure, hypertension, age > _75, diabetes mellitus, prior stroke or transient ischaemic attack, vascular disease, age 65 to 74, female (CHA 2 DS 2 -VASc) score. 
Strength and limitations
Through our nationwide registers it was possible to access data from an unselected cohort undergoing ablation with a minimum of potential selection bias. This access gives a great advantage over randomized controlled trials, which often exclude older patients and patients with high burden of comorbidity and polypharmacy. The results from our nationwide cohort study also derives from real life data, hence the results from our study can be applied directly to the patients in everyday clinical care. The risk of recurrent AF after an ablation is known to be considerably higher in patients with persistent AF compared with patients with paroxysmal AF or atrial flutter. In the current study design, no validated method of identifying AF type was available. This missing information could introduce bias by unmeasured confounders with risk of leaving residual confounding in our results.
In order to strengthen the associations found in our study, matched analyses were performed as sensitivity analyses to the main analyses. In addition, numerous subgroup analyses were performed to investigate if specific subgroups motivated the associations found in the main analyses.
Clinical data on risk factors for AF like blood pressure measurements and blood glucose would have been desirable. Similarly, no data on obesity, left ventricular ejection fraction, or left atrial size was available.
Clinical perspective
Rhythm control therapy is indicated for symptom improvement in patients with AF, and ablation is one of the treatment options with a rhythm control approach. 21 When referring a patient to an ablation procedure both patients and doctors should know of the individual patient's risk of recurrent AF after the ablation. This means that a more optimistic approach towards risk of recurrent AF can be taken towards a man without hypertension and short duration of AF than with a woman with hypertension and a long AF duration. Patients and doctors should also know that although the risk recurrent AF has decreased substantially from 2005-2006 to 2013-2014, in the total cohort of ablation patients, no improvement over time has been found in patients with diabetes, chronic kidney disease, heart failure, and long duration of AF (>2 years).
Conclusion
Over the last 8 years, the risk of recurrent AF after ablation has almost halved. Hypertension, female sex, cardioversion 1 year prior to ablation, and AF duration for more than 2 years all increased the associated risk of recurrent AF. The lower the CHA 2 DS 2 -VASc score the lower risk of recurrent AF. Patients with diabetes, chronic kidney disease, AF duration over 2 years, and patients with heart failure all experienced no improvement in risk of recurrent AF over time.
